For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Pulmonx Corp (NASDAQ: LUNG) closed at $1.6 up 2.56% from its previous closing price of $1.56. In other words, the price has increased by $2.56 from its previous closing price. On the day, 0.93 million shares were traded. LUNG stock price reached its highest trading level at $1.655 during the session, while it also had its lowest trading level at $1.56.
Ratios:
For a deeper understanding of Pulmonx Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.62 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.80.
On March 10, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $17.
Citigroup Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $17 to $7.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 12 ’25 when Ferrari Richard sold 8,000 shares for $3.16 per share. The transaction valued at 25,280 led to the insider holds 87,024 shares of the business.
Ferrari Richard bought 5,438 shares of LUNG for $16,368 on Jun 13 ’25. On Jun 12 ’25, another insider, RICH FERRARI, who serves as the Director of the company, bought 8,000 shares for $3.16 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 65194560 and an Enterprise Value of 37797488. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.72 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 0.417 whereas that against EBITDA is -0.701.
Stock Price History:
The Beta on a monthly basis for LUNG is 0.42, which has changed by -0.76978415 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, LUNG has reached a high of $9.37, while it has fallen to a 52-week low of $1.47. The 50-Day Moving Average of the stock is -38.25%, while the 200-Day Moving Average is calculated to be -69.25%.
Shares Statistics:
For the past three months, LUNG has traded an average of 566.74K shares per day and 931650 over the past ten days. A total of 40.74M shares are outstanding, with a floating share count of 35.94M. Insiders hold about 11.80% of the company’s shares, while institutions hold 84.55% stake in the company. Shares short for LUNG as of 1753920000 were 1368026 with a Short Ratio of 2.41, compared to 1751241600 on 1318828. Therefore, it implies a Short% of Shares Outstanding of 1368026 and a Short% of Float of 4.9200002.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.37 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.5 and -$1.6 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$1.33, with 6.0 analysts recommending between -$1.11 and -$1.58.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $20.78M this quarter.It ranges from a high estimate of $22M to a low estimate of $20M. As of the current estimate, Pulmonx Corp’s year-ago sales were $20.39MFor the next quarter, 6 analysts are estimating revenue of $23.43M. There is a high estimate of $24.06M for the next quarter, whereas the lowest estimate is $23M.
A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $91.77M, while the lowest revenue estimate was $90M, resulting in an average revenue estimate of $90.61M. In the same quarter a year ago, actual revenue was $83.79MBased on 6 analysts’ estimates, the company’s revenue will be $103.95M in the next fiscal year. The high estimate is $118.25M and the low estimate is $99.63M.
